A randomized, double-blind, split-faced study comparing A.I. Clearing Treatment with 0.1% adapalene versus 0.1% adapalene in treatment of mild to moderate degree acne vulgaris
Phase 2
- Conditions
- mild to moderate degree acne vulgarisacne vulgarisacneadapaleneglycolic acidsalicylic acidgluconolactonelicochalcone AmoistureA.I. Clearing Treatment
- Registration Number
- TCTR20171031005
- Lead Sponsor
- Beiersdorf (Thailand) Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
1. Male or female, 18-40 years old
2. Mild to moderate acne vulgaris by Acne Consensus Conference (ACC) criteria
Exclusion Criteria
1. previous phototherapy/laser within 4 weeks or use topical/systemic for treat acne within 2
2. who has other skin lesion or skin disease in study area
3. pregnancy or lactation
4. allergy to adapalene, glycolic acid, salicylic acid, gluconolactone, licochalcone A
5. immunocompromised host
6. psychiatric problem
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method inflammatory lesions of acne 0, 1, 2, 4 weeks counting
- Secondary Outcome Measures
Name Time Method erythema (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),scale (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),burning (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),itching (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),transpeidermal water loss 0, 1, 2, 4 weeks Tewameter®,skin hydration 0, 1, 2, 4 weeks Corneometer®,acne grading 0, 1, 2, 4 weeks Acne Consensus Conference (ACC),radiance visual analog scale 0, 1, 2, 4 weeks visual analog scale (VAS) for degree of sleepiness,Investigator’s Global Assessment Acne (IGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5),Patient’s Global Assessment Acne (PGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5)